Publications

Export 113 results:
Sort by: Author Title [ Type  (Desc)] Year
Miscellaneous
, , , unknown year. Abstract
n/a
Ragab, G., P. T. Atkinson, and M. L. Stoll, The Microbiome in Rheumatic Diseases and Infection, : Springer, 2018. Abstract
n/a
Cacoub, P., S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, L. Quatuccio, M. Hegazy, and T. Poynard, OP0235 Interferon-free antivirals for hepatitis c virus-associated cryoglobulinemia vasculitis: a long-term follow-up study, : BMJ Publishing Group Ltd, 2018. Abstract
n/a
Quartuccio, L., L. Corazza, M. Ramos-Casals, S. Retamozo, G. M. Ragab, G. Ferraccioli, E. Gremese, A. Tzioufas, M. Voulgarelis, and D. Vassilopoulos, OP0274 Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins, : BMJ Publishing Group Ltd, 2015. Abstract
n/a
Goubran, H., G. Ragab, and S. Hassouna, Precision Anticoagulation Medicine: A Practical Guide, : Springer Nature, 2019. Abstract
n/a
Al Saleh, J., G. Ragab, P. Nash, H. Halabi, A. Laatar, A. E. - S. M. Yousef, H. Ehsouna, and M. Hammoudeh, Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?, : Springer London, 2015. Abstract
n/a
Journal Article
Alnahas, Z., manal el menyawi, M. Fawzy, O. Shaker, and G. Ragab, "173. 25-HYDROXYVITAMIN D3 DEFICIENCY AND VITAMIN D RECEPTOR POLYMORPHISMS IN EGYPTIAN BEHÇET’S DISEASE PATIENTS: A PILOT STUDY", Rheumatology, vol. 58, issue Supplement_2: Oxford University Press, pp. kez060, 2019. Abstract
n/a
Al-Nahas, Z., M. Fawzy, manal el menyawi, O. Shaker, and G. Ragab, "25-hydroxyvitamin D3 deficiency and vitamin D receptor polymorphisms in Egyptian patients with Behçet’s disease: a pilot study", International Journal of Clinical Rheumatology, vol. 12, pp. 20-27, 2017. Abstract
n/a
Abdel Badaee, H., A. Edrees, S. Amin, M. Elamir, and G. Ragab, "Activated protein C resistance in Behcet's disease", Thrombosis Journal, vol. 11, issue 1, 2013. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Abdel Badaee, H., A. Edrees, S. Amin, M. El Amir, and G. Ragab, "Activated protein C resistance in Behcet's disease.", Thrombosis journal, vol. 11, issue 1, pp. 17, 2013. Abstract

Behcet's disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most frequent. Endothelial dysfunction resulting from vascular inflammation is considered to be an important factor of thrombosis, although the endothelial injury itself cannot completely explain the hypercoagulable state of the disease because other vasculitis syndromes do not increase the risk of thrombosis. The aim of this study is to evaluate the prevalence of activated protein C resistance (APC-R) in Egyptian patients with Behcet's disease. Also, to detect hyperhomocysteinemia in selected cases (with vascular complications) to assess their relationship with thromboembolic complications. The APC resistance ratio mean in the group of patients with vascular involvement was 2.6 ± 0.8 which was less than the group with no vascular involvement 2.8 ± 0.6, with non- significant P-value (0.5). There was more incidence of ocular lesions in the group of patients with high homocysteine level than the group of patients with normal homocytsteine level with significant P-value (0.08).

Abdel Badaee, H., A. Edrees, S. Amin, M. El Amir, and G. Ragab, "Activated protein C resistance in Behcet’s disease", Thrombosis journal, vol. 11, issue 1: BioMed Central, pp. 1-5, 2013. Abstract
n/a
Gaggiano, C., D. Rigante, J. Hernández-Rodríguez, A. Vitale, M. Tarsia, A. Soriano, G. Lopalco, F. Iannone, M. Abdel Jaber, R. Giacomelli, et al., "Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network", Therapeutic Advances in Musculoskeletal Disease, vol. 13: SAGE Publications Ltd, 2021. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective", Journal of Advanced Research, vol. 7, issue 3: Elsevier, pp. 391 - 402, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective.", Journal of advanced research, vol. 7, issue 3, pp. 391-402, 2016 May. Abstract

Egypt, the single country with highest incidence of HCV infection in the world, has embarked on a government-sponsored mass treatment program using several combinations of DAAs. Recognizing the importance of extrahepatic manifestations, independently of the hepatic, a subcommittee was assigned to develop national guidelines for respective prioritizing indications and protocols. It evaluated the benefit of treating patients with different extrahepatic manifestations, and reviewed relevant clinical trials and guidelines concerning DAA combinations available in Egypt. The latter included Sofosbuvir plus either peg-interferon, Simeprevir, Ledipasvir or daclatasvir, and the Viekera family comprising paritaprevir/ritonavir + ombitasvir with (GT-1) or without (GT-4) Dasabuvir. Any of these protocols may be used with or without Ribavirin according to indication. A blueprint was subjected to peer debate in dedicated workshops in two national meetings and subsequently to an online professional review, eventually leading to a final report that was adopted by the health authorities. Seven compelling and 10 optional indications were identified for treating patients with predominantly extrahepatic manifestations. The former include kidney disease at different stages, cryoglobulinemic vasculitis and non-Hodgkin lymphoma. Selected treatment protocols, were encoded and their use was prioritized on the basis of evidence of efficacy and safety. We concluded that any of the studied protocols may be used, preferably with ribavirin, for 12-week treatment in all patients with extrahepatic manifestations without cirrhosis and with eGFR above 30 ml/min/1.73 sqm. Ribavirin should be included in protocols for treating patients with compensated cirrhosis. Daclatasvir-based protocols are recommended for decompensated cirrhosis, while the Viekera family is recommended in patients with eGFR < 30 ml/min/1.73 sqm, including those on dialysis. In kidney-transplanted patents, caution is due to avoidance of the pharmacokinetic interaction with the Cytochrome-P450 enzyme system, in-between immunosuppressive agents and most DAAs, particularly the Viekera family.

El-Fishawy, H., G. Saadi, M. Hassaballa, M. Hussein, W. Doss, G. Ragab, and R. Barsoum, "Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations–An Egyptian perspective", Journal of advanced research, vol. 7, issue 3: Elsevier, pp. 391-402, 2016. Abstract
n/a
Pusiol, A., F. Marzona, D. Cucchiaro, L. Castriotta, S. Usai, M. Narduzzi, C. Pilotto, I. Liguoro, R. Tosolini, and E. Passone, "Articles online first", Minerva Pediatrica, 2020. Abstract
n/a
Hegab, M. M., A. F. Abdelwahab, A. E. - S. M. Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, and S. M. Ibrahim, "CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians", Human immunology, vol. 77, issue 6: Elsevier, pp. 522-526, 2016. Abstract
n/a
Hegab, M. M., A. F. Abdelwahab, A. M. El-Sayed Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, S. M. Ibrahim, et al., "CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians", Human Immunology, vol. 77, issue 6: Elsevier Inc., pp. 522 - 526, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hegab, M. M., A. F. Abdelwahab, A. M. El-Sayed Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, S. M. Ibrahim, et al., "CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians.", Human immunology, vol. 77, issue 6, pp. 522-6, 2016 Jun. Abstract

OBJECTIVE: Limited data are available on the genetics of rheumatoid arthritis (RA) in Egyptians. Therefore, we investigated whether the confirmed genetic risk factors for RA in Europeans and/or Asians contribute to RA susceptibility in Egyptians.

SUBJECTS AND METHODS: A set of seven single-nucleotide polymorphisms (SNPs) in the vicinity of CD28, TNFAIP3, PTPN22, PADI4 and HLA-DRA were tested in a large multi-centric RA cohort in Egypt, consisting of 394 cases and 398 matched controls. Patients were stratified based on the positivity of either anti-citrullinated protein antibodies (ACPAs) or rheumatoid factor (RF).

RESULTS: Significant association was evident for three SNPs in this cohort: the CD28 (rs1980422) variant showed a strong association in the whole cohort (P=0.000119) and in seropositive subsets of the disease (PACPA+=0.004; PRF+=0.0005). Upon stratification, the PTPN22 (rs2476601) and TNFAIP3(rs5029939) variants showed association only with ACPA positive (PACPA+=0.00573) and negative (PACPA-=0.00999) phenotypes, respectively.

CONCLUSION: Our results suggest that CD28(rs1980422) and PTPN22(rs2476601) contribute to RA-susceptibility in Egyptians. Failure to replicate the association of PADI4(rs2240340)/(PADI4_94) in Egyptian RA patients provides further support for the notion that genetic architecture of RA is different in multiple populations of European, Asian, African, and Middle Eastern ancestries. Further investigation using large-scale studies is thus needed to maximize the power of genetic association.

DeVore, A. E., J. L. Jorizzo, N. Vigneswaran, B. K. Rodu, S. Onal, S. C. Foster, S. K. Frankel, M. I. Schwarz, S. J. Oh, G. Ragab, et al., "Clinical manifestations common to vasculitis", Vasculitis: Oxford University Press, pp. 115, 2007. Abstract
n/a
DeVore, A. E., J. L. Jorizzo, N. Vigneswaran, B. K. Rodu, S. Onal, S. C. Foster, S. K. Frankel, M. I. Schwarz, S. J. Oh, and G. Ragab, "Clinical manifestations common to vasculitis", Vasculitis: Oxford University Press, pp. 115, 2007. Abstract
n/a
Hegab, M. M., A. F. Abdelwahab, J. M. Rudolph, A. M. El-Sayed Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, et al., "Corrigendum to ?CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians? [Hum. Immunol. 77 (2016) 522?526] (S0198885916300684), (10.1016/j.humimm.2016.04.018))", Human Immunology, vol. 78, no. 7-8, 2017. Abstract
n/a
Hegab, M. M., A. F. Abdelwahab, J. M. Rudolph, A. M. El-Sayed Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, W. Abouraya, et al., "Corrigendum to “CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians” [Hum. Immunol. 77 (2016) 522–526] (S0198885916300684), (10.1016/j.humimm.2016.04.018))", Human Immunology, vol. 78, issue 7-8: Elsevier Inc., pp. 521, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hegab, M. M., A. F. Abdelwahab, J. M. Rudolph, A. E. - S. M. Yousef, M. N. Salem, W. El-Baz, S. Abdelrhman, F. Elshabacy, A. Alhefny, and W. Abouraya, "Corrigendum to" CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians"[Hum. Immunol. 77 (2016) 522-526]", Human immunology, vol. 78, issue 7-8, pp. 521, 2017. Abstract
n/a
Vitale, A., F. Della Casa, G. Ragab, I. A. Almaghlouth, G. Lopalco, R. M. Pereira, S. Guerriero, M. Govoni, P. P. Sfikakis, R. Giacomelli, et al., "Development and implementation of the AIDA International Registry for patients with Behçet’s disease", Internal and Emergency Medicine: Springer Science and Business Media Deutschland GmbH, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Della Casa, F., A. Vitale, R. M. Pereira, S. Guerriero, G. Ragab, G. Lopalco, M. Cattalini, I. Mattioli, P. Parronchi, M. P. Paroli, et al., "Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis", Ophthalmology and Therapy, vol. 11, issue 2: Adis, pp. 887 - 897, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Casa, F. D., A. Vitale, S. Guerriero, J. Sota, R. Cimaz, G. Ragab, P. Ruscitti, R. M. R. Pereira, F. Minoia, E. Del Giudice, et al., "Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis", Ophthalmology and Therapy, vol. 11, issue 2: Adis, pp. 899 - 911, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Vitale, A., F. Della Casa, G. Lopalco, R. M. Pereira, P. Ruscitti, R. Giacomelli, G. Ragab, F. La Torre, E. Bartoloni, E. Del Giudice, et al., "Development and Implementation of the AIDA International Registry for Patients With Still's Disease", Frontiers in Medicine, vol. 9: Frontiers Media S.A., 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Della Casa, F., A. Vitale, G. Lopalco, P. Ruscitti, F. Ciccia, G. Emmi, M. Cattalini, E. Wiesik-Szewczyk, M. C. Maggio, B. Ogunjimi, et al., "Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases", Frontiers in Medicine, vol. 9: Frontiers Media S.A., 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Sota, J., D. Rigante, R. Cimaz, M. Cattalini, M. Frassi, R. Manna, L. L. Sicignano, E. Verrecchia, E. Aragona, and M. C. Maggio, "Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry", Rheumatology, 2021. Abstract
n/a
Sota, J., D. Rigante, R. Cimaz, M. Cattalini, M. Frassi, R. Manna, L. L. Sicignano, E. Verrecchia, E. Aragona, M. C. Maggio, et al., "Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: Observational study from the International AIDA Registry", Rheumatology (United Kingdom), vol. 60, issue 12: Oxford University Press, pp. 5705 - 5712, 2021. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Moawad, P., R. Shamma, D. Hassanein, G. Ragab, and O. El Zawahry, "Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome", European Journal of Ophthalmology, vol. 32, issue 1: SAGE Publications Ltd, pp. 673 - 679, 2022. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Hussein, M., A. El-Hindawi, and G. Ragab, "Everolimus in Erdheim–Chester disease", The Egyptian Journal of Internal Medicine, vol. 25, issue 3, pp. 159 - 163, 2013/9/1. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ

A 43-year-old man presented with bony pains, repeated pathological fractures with overlying skin ulcerations, and forearm and chest wall swellings. Investigations led to the diagnosis of Erdheim–Chester disease. Treatment with low-dose prednisolone, oral everolimus, and zoledronic acid was started, with a marked improvement in his condition.

Hussein, M. A., A. El-Hindawi, and G. Ragab, "Everolimus in Erdheim–Chester disease", The Egyptian Journal of Internal Medicine, vol. 25, issue 3: SpringerOpen, pp. 159-163, 2013. Abstract
n/a
Ramos-Casals, M., A. L. Zignego, C. Ferri, P. Brito-Zerón, S. Retamozo, M. Casato, P. Lamprecht, A. Mangia, D. Saadoun, A. G. Tzioufas, et al., "Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection", Journal of Hepatology, vol. 66, no. 6: Elsevier {BV}, pp. 1282–1299, jun, 2017. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Ramos-Casals, M., A. L. Zignego, C. Ferri, P. Brito-Zeron, S. Retamozo, M. Casato, P. Lamprecht, A. Mangia, D. Saadoun, and A. G. Tzioufas, "Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection", Journal of Hepatology, vol. 66, issue 6: Elsevier, pp. 1282-1299, 2017. Abstract
n/a
M Fawzy, A Edrees, O. E. A. R. H. A. G., "Gastrointestinal manifestations in systemic lupus erythematosus", Lupus, 2016. Abstract
n/a
Fawzy, M., A. Edrees, H. Okasha, A. El Ashmaui, and G. Ragab, "Gastrointestinal manifestations in systemic lupus erythematosus", Lupus, vol. 25, issue 13: SAGE Publications Ltd, pp. 1456 - 1462, 2016. Abstracthttps://scholar.google.com.eg/citations?hl=en&user=7L5p7RYAAAAJ
n/a
Fawzy, M., A. Edrees, H. Okasha, A. El Ashmaui, and G. Ragab, "Gastrointestinal manifestations in systemic lupus erythematosus.", Lupus, 2016 Apr 6. Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by multisystem involvement, including the gastrointestinal (GI) tract. There is a significant variation in the clinical presentation and severity of GI disorders. When GI symptoms present as the initial manifestation of SLE, there is likely to be a delay in the diagnosis. The cause of these GI manifestations in SLE may be the disease, or the side effects of medications, or infections. In this study we investigated the GI manifestations in a group of SLE patients. Our study was conducted on 40 SLE patients and 30 healthy controls to assess the prevalence of GI symptoms in SLE patients. The prevalence of gastrointestinal manifestations in our study was 42.5%. GI manifestations in our SLE patients were: acute abdominal pain (due to pleurisy and peritonitis), 6%; diffuse abdominal pain, 23.5%; epigastric pain, 29%; epigastric pain with vomiting, 23.5%; epigastric pain with chronic constipation, 6%; chronic constipation, 6%; and diffuse abdominal pain with bleeding per rectum, 6%. In our study, we found a higher incidence ofGiardiainfestation in SLE patients than in healthy controls, and 10% of these patients were asymptomatic. There was moreGiardiainfestation in patients with GI symptoms as compared with patients with no GI symptoms, with aPvalue of 0.009. In our study SLE patients with GI symptoms had a peak systolic velocity (cm/s) with a mean of 108.4 ± 32.1 standard deviation (SD) in the celiac Doppler study. Patients without GI symptoms had a peak systolic velocity with a mean of 111.9 ± 37.7 SD, meaning that our patients mostly had no evidence of celiac trunk stenosis, but there was significant difference between SLE patients without GI symptoms and controls, as the mean was higher in SLE patients than in the controls. Also, the celiac end diastolic velocity was higher in both groups of SLE patients with GI symptoms and those without GI symptoms, compared to controls.

Tourism